ClinicalTrials.gg
Not yet recruitingNCT07411040Updated Feb 13, 2026

Effects of Body Awareness Therapy on Physical and Psychosocial Outcomes in Adults With Asthma

An interventional study of Body Awareness Therapy and Standart Care in Asthma, sponsored by Recep Tayyip Erdogan University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Recep Tayyip Erdogan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to investigate the effects of Body Awareness Therapy on physical and psychosocial outcomes in adults with asthma. Asthma is a chronic respiratory condition that can affect breathing, physical activity, and emotional well-being. In addition to medical treatment, non-pharmacological approaches that support body awareness and breathing may help individuals manage their symptoms more effectively.

Participants in this study will be randomly assigned to either a Body Awareness Therapy group or a control group receiving standard care. The Body Awareness Therapy program includes guided exercises focusing on posture, breathing, movement, and awareness of bodily sensations. The program will be delivered over several weeks by a trained physiotherapist.

The main outcomes of the study include physical function, respiratory symptoms, quality of life, psychological well-being, and body awareness levels. The results of this study are expected to provide evidence on whether Body Awareness Therapy can be an effective supportive approach in asthma management and rehabilitation.

Read the detailed description

This study is designed to evaluate the effectiveness of Body Awareness Therapy as a complementary intervention for adults with asthma. Asthma is a chronic inflammatory airway disease that not only affects respiratory function but is also associated with reduced physical capacity, increased symptom perception, psychological distress, and decreased quality of life. While pharmacological treatment is essential for asthma management, many individuals continue to experience persistent symptoms and psychosocial challenges despite optimal medical care.

Body Awareness Therapy is a mind-body approach that emphasizes conscious attention to bodily sensations, breathing patterns, posture, and movement. The therapy aims to improve self-regulation, enhance interoceptive awareness, and promote more efficient and relaxed breathing. Previous research in other chronic conditions suggests that body-based interventions may positively influence physical function, symptom perception, emotional well-being, and coping strategies. However, evidence regarding the use of Body Awareness Therapy in individuals with asthma remains limited.

In this randomized controlled trial, eligible participants will be randomly allocated to either a Body Awareness Therapy group or a control group receiving standard care. The intervention will consist of supervised sessions conducted by a trained physiotherapist over a predefined period. The sessions will include guided exercises focusing on breathing awareness, postural alignment, gentle movement, and attention to bodily sensations. Participants will also be encouraged to apply these principles in daily life.

The primary outcomes of the study include physical function and asthma-related symptoms. Secondary outcomes include psychological well-being, quality of life, and levels of body awareness. Outcome measures will be assessed at baseline and after completion of the intervention period.

The findings of this study are expected to contribute to the growing field of non-pharmacological and mind-body interventions in respiratory rehabilitation. If effective, Body Awareness Therapy may represent a low-cost, safe, and accessible supportive approach to improve both physical and psychosocial health in individuals with asthma.

02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • body awareness
  • body awareness therapy
03

In context

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

This study's planned enrollment of 67 is below the median of 79 across 3,346 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Recep Tayyip Erdogan University is the lead sponsor of 69 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged between 18 and 65 years.
  • Clinically diagnosed asthma confirmed by a physician.
  • Stable asthma condition (no acute exacerbation in the last 4 weeks).
  • Receiving regular medical treatment for asthma.
  • Able to understand and follow instructions for the intervention.
  • Willing to participate and provide written .

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of chronic respiratory diseases other than asthma (e.g., , bronchiectasis).
  • Acute asthma exacerbation within the last 4 weeks.
  • Severe cardiovascular, neurological, or musculoskeletal conditions that may limit participation in physical activity.
  • Current participation in another structured exercise or rehabilitation program.
  • History of major psychiatric disorders that may interfere with participation (e.g., psychotic disorders).
  • Pregnancy.
  • Cognitive impairment affecting the ability to follow instructions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    Body Awareness Therapy Group

    Participants will receive a structured Body Awareness Therapy program delivered by a trained physiotherapist.

    Behavioral: Body Awareness Therapy · Other: Standart Care

  • Active comparator
    Standard Care Control Group

    Participants will receive standard medical care for asthma without additional body awareness intervention.

    Other: Standart Care

Interventions

  • BehavioralBody Awareness Therapy

    A structured Body Awareness Therapy program delivered by a trained physiotherapist, including guided exercises focusing on breathing awareness, posture, gentle movement, and attention to bodily sensations.

  • OtherStandart Care

    Participants will continue their usual medical care for asthma without additional body awareness intervention.

06

What researchers measure

Primary outcomes

  1. Six-Minute Walk Test Distance

    Physical function will be assessed using the Six-Minute Walk Test (6MWT). Total walking distance covered in six minutes will be recorded. (Units of Measure: Meters)

    Time frame: Baseline (Week 0) and Post-intervention (Week 8)

  2. Asthma Control Test Total Score

    Asthma symptom severity will be assessed using the Turkish Asthma Control Test (T-ACT). The total questionnaire score will be analyzed.

    Time frame: Baseline (Week 0) and Post-intervention (Week 8)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared publicly due to ethical and privacy considerations, as the data include sensitive personal and health-related information. Data will be used only for the purposes of the current study and stored in accordance with institutional and data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Apr 2026, 2 months later.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 2 months is below that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2026
First posted
Feb 13, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Apr 1, 2026
CompletionEst.
May 1, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07411040
Lead sponsor
Recep Tayyip Erdogan University
Collaborators
İstanbul Yeni Yüzyıl Üniversitesi
Responsible party
Seda Karaca (Dr, Recep Tayyip Erdogan University) — Principal investigator
First posted
Feb 13, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion